Antiandrogens in Prostate Cancer: A Key to Tailored Endocrine Treatment
The introduction of maximal androgen blockade as a clinical therapy by Brachi and Labrie more than a decade ago led to a huge controversy on the clinical use of antiandrogens in the treatment of prostate cancer. Three consensus meetings were subsequently organized with the support of the American Ca...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Berlin, Heidelberg
Springer Berlin Heidelberg
1996
|
| Schriftenreihe: | ESO Monographs, European School of Oncology
|
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | The introduction of maximal androgen blockade as a clinical therapy by Brachi and Labrie more than a decade ago led to a huge controversy on the clinical use of antiandrogens in the treatment of prostate cancer. Three consensus meetings were subsequently organized with the support of the American Cancer Society, the Urological Group of the European Organization for Research and Treatment of Cancer and the International Prostate Health Council. The first results of the meta-analysis of 22 trials did not put an end to the controversy, however, and clinicians were left confused by conflicting reports published by dozens of experts. The meeting behind the present volume created a forum for the scientists who developed the drugs and specialist clinicians to produce a consensus. The result is an overview of the field, condensed from hundreds of publications. The information has been updated to provide precise clinical indications for the use of antiandrogens in combination treatments and monotherapy for the individual patient. We hope that this team effort will facilitate ongoing discussions and lead to improved patient care as well as increased knowledge of the drugs that are so vital to our patients' quality of life and survival |
| Beschreibung: | 1 Online-Ressource (VII, 120 p) |
| ISBN: | 9783642457456 |
| DOI: | 10.1007/978-3-642-45745-6 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046143952 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s1996 |||| o||u| ||||||eng d | ||
| 020 | |a 9783642457456 |9 978-3-642-45745-6 | ||
| 024 | 7 | |a 10.1007/978-3-642-45745-6 |2 doi | |
| 035 | |a (ZDB-2-SME)978-3-642-45745-6 | ||
| 035 | |a (OCoLC)1119112124 | ||
| 035 | |a (DE-599)BVBBV046143952 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.994 |2 23 | |
| 084 | |a XH 8015 |0 (DE-625)152949:13144 |2 rvk | ||
| 084 | |a YH 8000 |0 (DE-625)153583:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Antiandrogens in Prostate Cancer |b A Key to Tailored Endocrine Treatment |c edited by Louis Denis |
| 264 | 1 | |a Berlin, Heidelberg |b Springer Berlin Heidelberg |c 1996 | |
| 300 | |a 1 Online-Ressource (VII, 120 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a ESO Monographs, European School of Oncology | |
| 520 | |a The introduction of maximal androgen blockade as a clinical therapy by Brachi and Labrie more than a decade ago led to a huge controversy on the clinical use of antiandrogens in the treatment of prostate cancer. Three consensus meetings were subsequently organized with the support of the American Cancer Society, the Urological Group of the European Organization for Research and Treatment of Cancer and the International Prostate Health Council. The first results of the meta-analysis of 22 trials did not put an end to the controversy, however, and clinicians were left confused by conflicting reports published by dozens of experts. The meeting behind the present volume created a forum for the scientists who developed the drugs and specialist clinicians to produce a consensus. The result is an overview of the field, condensed from hundreds of publications. The information has been updated to provide precise clinical indications for the use of antiandrogens in combination treatments and monotherapy for the individual patient. We hope that this team effort will facilitate ongoing discussions and lead to improved patient care as well as increased knowledge of the drugs that are so vital to our patients' quality of life and survival | ||
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Oncology | |
| 650 | 0 | 7 | |a Antiandrogene |0 (DE-588)4137601-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Prostatakrebs |0 (DE-588)4047511-6 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Prostatakrebs |0 (DE-588)4047511-6 |D s |
| 689 | 0 | 1 | |a Antiandrogene |0 (DE-588)4137601-8 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Denis, Louis |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642457470 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783540605997 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642457463 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-642-45745-6 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031524135 | ||
| 966 | e | |u https://doi.org/10.1007/978-3-642-45745-6 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180478691901440 |
|---|---|
| any_adam_object | |
| author2 | Denis, Louis |
| author2_role | edt |
| author2_variant | l d ld |
| author_facet | Denis, Louis |
| building | Verbundindex |
| bvnumber | BV046143952 |
| classification_rvk | XH 8015 YH 8000 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-3-642-45745-6 (OCoLC)1119112124 (DE-599)BVBBV046143952 |
| dewey-full | 616.994 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994 |
| dewey-search | 616.994 |
| dewey-sort | 3616.994 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-3-642-45745-6 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03178nmm a2200517zc 4500</leader><controlfield tag="001">BV046143952</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1996 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783642457456</subfield><subfield code="9">978-3-642-45745-6</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-642-45745-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-3-642-45745-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119112124</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046143952</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 8015</subfield><subfield code="0">(DE-625)152949:13144</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YH 8000</subfield><subfield code="0">(DE-625)153583:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antiandrogens in Prostate Cancer</subfield><subfield code="b">A Key to Tailored Endocrine Treatment</subfield><subfield code="c">edited by Louis Denis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin, Heidelberg</subfield><subfield code="b">Springer Berlin Heidelberg</subfield><subfield code="c">1996</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (VII, 120 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">ESO Monographs, European School of Oncology</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The introduction of maximal androgen blockade as a clinical therapy by Brachi and Labrie more than a decade ago led to a huge controversy on the clinical use of antiandrogens in the treatment of prostate cancer. Three consensus meetings were subsequently organized with the support of the American Cancer Society, the Urological Group of the European Organization for Research and Treatment of Cancer and the International Prostate Health Council. The first results of the meta-analysis of 22 trials did not put an end to the controversy, however, and clinicians were left confused by conflicting reports published by dozens of experts. The meeting behind the present volume created a forum for the scientists who developed the drugs and specialist clinicians to produce a consensus. The result is an overview of the field, condensed from hundreds of publications. The information has been updated to provide precise clinical indications for the use of antiandrogens in combination treatments and monotherapy for the individual patient. We hope that this team effort will facilitate ongoing discussions and lead to improved patient care as well as increased knowledge of the drugs that are so vital to our patients' quality of life and survival</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology </subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Antiandrogene</subfield><subfield code="0">(DE-588)4137601-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Prostatakrebs</subfield><subfield code="0">(DE-588)4047511-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Prostatakrebs</subfield><subfield code="0">(DE-588)4047511-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Antiandrogene</subfield><subfield code="0">(DE-588)4137601-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Denis, Louis</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642457470</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783540605997</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642457463</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-3-642-45745-6</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031524135</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-3-642-45745-6</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV046143952 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:24Z |
| institution | BVB |
| isbn | 9783642457456 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031524135 |
| oclc_num | 1119112124 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (VII, 120 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 1996 |
| publishDateSearch | 1996 |
| publishDateSort | 1996 |
| publisher | Springer Berlin Heidelberg |
| record_format | marc |
| series2 | ESO Monographs, European School of Oncology |
| spelling | Antiandrogens in Prostate Cancer A Key to Tailored Endocrine Treatment edited by Louis Denis Berlin, Heidelberg Springer Berlin Heidelberg 1996 1 Online-Ressource (VII, 120 p) txt rdacontent c rdamedia cr rdacarrier ESO Monographs, European School of Oncology The introduction of maximal androgen blockade as a clinical therapy by Brachi and Labrie more than a decade ago led to a huge controversy on the clinical use of antiandrogens in the treatment of prostate cancer. Three consensus meetings were subsequently organized with the support of the American Cancer Society, the Urological Group of the European Organization for Research and Treatment of Cancer and the International Prostate Health Council. The first results of the meta-analysis of 22 trials did not put an end to the controversy, however, and clinicians were left confused by conflicting reports published by dozens of experts. The meeting behind the present volume created a forum for the scientists who developed the drugs and specialist clinicians to produce a consensus. The result is an overview of the field, condensed from hundreds of publications. The information has been updated to provide precise clinical indications for the use of antiandrogens in combination treatments and monotherapy for the individual patient. We hope that this team effort will facilitate ongoing discussions and lead to improved patient care as well as increased knowledge of the drugs that are so vital to our patients' quality of life and survival Oncology Oncology Antiandrogene (DE-588)4137601-8 gnd rswk-swf Prostatakrebs (DE-588)4047511-6 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Prostatakrebs (DE-588)4047511-6 s Antiandrogene (DE-588)4137601-8 s DE-604 Denis, Louis edt Erscheint auch als Druck-Ausgabe 9783642457470 Erscheint auch als Druck-Ausgabe 9783540605997 Erscheint auch als Druck-Ausgabe 9783642457463 https://doi.org/10.1007/978-3-642-45745-6 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Antiandrogens in Prostate Cancer A Key to Tailored Endocrine Treatment Oncology Oncology Antiandrogene (DE-588)4137601-8 gnd Prostatakrebs (DE-588)4047511-6 gnd |
| subject_GND | (DE-588)4137601-8 (DE-588)4047511-6 (DE-588)4143413-4 |
| title | Antiandrogens in Prostate Cancer A Key to Tailored Endocrine Treatment |
| title_auth | Antiandrogens in Prostate Cancer A Key to Tailored Endocrine Treatment |
| title_exact_search | Antiandrogens in Prostate Cancer A Key to Tailored Endocrine Treatment |
| title_full | Antiandrogens in Prostate Cancer A Key to Tailored Endocrine Treatment edited by Louis Denis |
| title_fullStr | Antiandrogens in Prostate Cancer A Key to Tailored Endocrine Treatment edited by Louis Denis |
| title_full_unstemmed | Antiandrogens in Prostate Cancer A Key to Tailored Endocrine Treatment edited by Louis Denis |
| title_short | Antiandrogens in Prostate Cancer |
| title_sort | antiandrogens in prostate cancer a key to tailored endocrine treatment |
| title_sub | A Key to Tailored Endocrine Treatment |
| topic | Oncology Oncology Antiandrogene (DE-588)4137601-8 gnd Prostatakrebs (DE-588)4047511-6 gnd |
| topic_facet | Oncology Oncology Antiandrogene Prostatakrebs Aufsatzsammlung |
| url | https://doi.org/10.1007/978-3-642-45745-6 |
| work_keys_str_mv | AT denislouis antiandrogensinprostatecancerakeytotailoredendocrinetreatment |